Shots:

• Sanofi to get an exclusivity period for negotiating the in-licensing of KN026 with achievement of certain clinical milestones. The companies have initiated the enrollment for patients in the study which will evaluate KN026 +Taxotere (Docetaxel) in patients with HER2+ breast cancer
• The focus of the agreement is to advance clinical studies to evaluate KN026 in patients with HER2 + breast cancer in China further leading to expansion of its footprints
• Alphamab’s KN026 is an anti-HER2 bispecific Ab developed utilizing its CRIB (Charge Repulsion Induced Bispecific) a Fc-based heterodimer bispecific platform technology. In 2018- the candidate received NMPA and US FDA’s approval for IND and has shown safety- tolerance- and superior anti-tumor activity in P-I trial for HER2+ breast cancer patients progressed after multiple lines of anti-HER2 treatment

Click here to read full press release/ article | Ref: PRNewswire | Image: Signbox